Your browser doesn't support javascript.
loading
The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
Verma, Atul; Ha, Andrew C T; Kirchhof, Paulus; Hindricks, Gerhard; Healey, Jeff S; Hill, Michael D; Sharma, Mukul; Wyse, D George; Champagne, Jean; Essebag, Vidal; Wells, George; Gupta, Dhiraj; Heidbuchel, Hein; Sanders, Prashanthan; Birnie, David H.
Affiliation
  • Verma A; Southlake Regional Health Centre, Newmarket, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: atul.verma@utoronto.ca.
  • Ha ACT; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
  • Kirchhof P; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; UK SWBH NHS Trust, Birmingham, United Kingdom; UHB NHS Trust, Birmingham, United Kingdom; Atrial Fibrillation NETwork (AFNET), Münster, Germany; Department of Cardiovascular Medicine, Hospital of the Universi
  • Hindricks G; Heart Center, University of Leipzig, Department of Electrophysiology, Leipzig, Germany.
  • Healey JS; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
  • Hill MD; Department of Clinical Neurosciences and Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Sharma M; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
  • Wyse DG; Department of Cardiac Sciences and Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Champagne J; Institut Universitaire de Cardiologiee Pneumologie de Québec, Quebec City, Québec, Canada.
  • Essebag V; McGill University Health Centre, Montreal, Québec, Canada; Hôpital Sacré-Coeur de Montréal, Montreal, Québec, Canada.
  • Wells G; University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
  • Gupta D; Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.
  • Heidbuchel H; University Antwerp and University Hospital Antwerp, Antwerp, Belgium.
  • Sanders P; University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia.
  • Birnie DH; University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Am Heart J ; 197: 124-132, 2018 03.
Article in En | MEDLINE | ID: mdl-29447772
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Atrial Fibrillation / Ischemic Attack, Transient / Aspirin / Catheter Ablation / Stroke / Rivaroxaban Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: Am Heart J Year: 2018 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Atrial Fibrillation / Ischemic Attack, Transient / Aspirin / Catheter Ablation / Stroke / Rivaroxaban Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: Am Heart J Year: 2018 Type: Article